Skip to main content
SpringerLink
Log in

MicroRNA-92a in Cardiovascular Disease: An Insufficiently Explored and Controversial Research Area

  • Letter to the Editor
  • Published:
Cardiovascular Drugs and Therapy Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Data Availability

Not applicable.

Code Availability

Not applicable.

References

  1. Wu Q, Wang H, He F, et al. Depletion of microRNA-92a enhances the role of sevoflurane treatment in reducing myocardial ischemia–reperfusion injury by upregulating KLF4. Cardiovasc Drugs Ther. 2022. https://doi.org/10.1007/s10557-021-07303-x.

  2. Hinkel R, Penzkofer D, Zühlke S, et al. Inhibition of microRNA-92a protects against ischemia/reperfusion injury in a large-animal model. Circulation. 2013;128(10):1066–75.

    Article  CAS  PubMed  Google Scholar 

  3. Zhang B, Zhou M, Li C, et al. MicroRNA-92a inhibition attenuates hypoxia/reoxygenation-induced myocardiocyte apoptosis by targeting Smad7. PLoS One. 2014;9(6):e100298.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Jiang F, Zhang B, Zhang X, et al. miRNA-92a inhibits vascular smooth muscle cell phenotypic modulation and may help prevent in-stent restenosis. Mol Med Rep. 2023;27(2):40.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Ma M, Li H, Yin S, Lin T, Song T. Overexpression of miR-92a attenuates kidney ischemia-reperfusion injury and improves kidney preservation by inhibiting MEK4/JNK1-related autophagy. Cell Mol Biol Lett. 2023;28(1):20.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Funding

The authors received no financial support for the research, authorship, and/or publication of this article.

Author information

Authors and Affiliations

  1. Department of Cardiology, The Second People’s Hospital of Liaocheng, Liaocheng, 252000, People’s Republic of China

    Jin-Zhen Cui & Yue-Min Yuan

  2. Department of General Practice, Liaocheng People’s Hospital and Clinical School of Taishan Medical University, Liaocheng, 252000, People’s Republic of China

    Yan-Yu Lin

Authors
  1. Jin-Zhen Cui
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yue-Min Yuan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yan-Yu Lin
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Jin-Zhen Cui and Yue-Min Yuan edited the manuscript. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Yan-Yu Lin.

Ethics declarations

Ethics Statement

Not applicable.

Consent for Publication

Not applicable.

Conflict of Interest

The authors report no relationships that could be construed as a conflict of interest.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Cui, JZ., Yuan, YM. & Lin, YY. MicroRNA-92a in Cardiovascular Disease: An Insufficiently Explored and Controversial Research Area. Cardiovasc Drugs Ther 38, 423–424 (2024). https://doi.org/10.1007/s10557-023-07533-1

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10557-023-07533-1

Search

Navigation